Amneal Pharmaceuticals held its 2026 Annual Meeting on May 6, 2026, where all director nominees were elected and all proposals, including executive compensation and auditor ratification, were approved by stockholders.
Key takeaways
All ten director nominees elected with overwhelming majorities, ranging from 237M to 270M for votes.
Advisory approval of named executive officer compensation with 269M for votes.
Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026, with 293M for votes.
Annual Meeting held on May 6, 2026; directors to serve until 2027 Annual Meeting.
Broker non-votes totaled 21,948,638 across director election proposals.